Tipco Foods Public Company Limited and its subsidiaries Report and interim consolidated financial statements For the three-month and nine-month periods ended 30 September 2019

# Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Tipco Foods Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Tipco Foods Public Company Limited and its subsidiaries as at 30 September 2019, the related consolidated statements of comprehensive income for the three-month and nine-month periods then ended, the related consolidated statement of changes in shareholders' equity and cash flows for the nine-month period then ended, as well as the condensed notes to the consolidated financial statements. I have also reviewed the separate financial information of Tipco Foods Public Company Limited for the same period. Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*. My responsibility is to express a conclusion on this interim financial information based on my review.

# Scope of review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity.* A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

# Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*.

Natthawut Santipet Certified Public Accountant (Thailand) No. 5730

EY Office Limited Bangkok: 13 November 2019

Statements of financial position

As at 30 September 2019

		Consolidated fina	ancial statements	Separate finan	cial statements		
	Note	30 September 2019	31 December 2018	30 September 2019	31 December 2018		
		(Unaudited	(Audited)	(Unaudited	(Audited)		
		but reviewed)		but reviewed)			
Assets							
Current assets							
Cash and cash equivalents		59,215	105,836	23,399	21,595		
Current investment		4,994	4,951	-	-		
Trade and other receivables	2, 3	399,874	562,332	29,075	45,474		
Short-term loans to related parties	2	-	-	121,000	90,000		
Inventories	4	754,614	986,475	60,762	61,973		
Biological assets		1,650	659	-	-		
Advance payments		39,342	12,268	4,515	4,205		
Other current assets		64,090	75,393	8,264	13,036		
Total current assets		1,323,779	1,747,914	247,015	236,283		
Non-current assets							
Investments in subsidiaries	5	-	-	1,765,337	1,765,337		
Investment in associate	6	3,046,225	2,910,063	644,930	644,930		
Investment property - Land awaiting sale		7,270	7,270	7,270	7,270		
Property, plant and equipment	7	2,208,666	2,287,283	714,203	742,168		
Intangible assets		39,774	56,194	27,832	30,237		
Deferred tax assets - net		54,833	47,379	5,295	3,588		
Other non-current assets		15,240	20,471	3,446	3,089		
Total non-current assets		5,372,008	5,328,660	3,168,313	3,196,619		
Total assets		6,695,787	7,076,574	3,415,328	3,432,902		

(Unit: Thousand Baht)

Statements of financial position (continued)

As at 30 September 2019

				(2			
		Consolidated fina	ancial statements	Separate financial statements			
	Note	30 September 2019	31 December 2018	30 September 2019	31 December 2018		
		(Unaudited	(Audited)	(Unaudited	(Audited)		
		but reviewed)		but reviewed)			
Liabilities and shareholders' equity							
Current liabilities							
Bank overdrafts and short-term loans from							
financial institutions		685,154	770,000	300,000	240,000		
Trade and other payables	2, 8	539,521	790,129	52,359	76,869		
Current portion of liabilities under finance							
lease agreement		653	-	653	-		
Current portion of long-term loans							
from financial institutions	9	405,000	312,500	223,700	201,200		
Income tax payable		-	10,693	-	-		
Other current liabilities		66,429	79,005	15,043	3,163		
Total current liabilities		1,696,757	1,962,327	591,755	521,232		
Non-current liabilities							
Liabilities under finance lease agreement							
- net of current portion		3,540	-	3,540	-		
Long-term loans from financial institutions							
- net of current portion	9	885,075	840,203	612,845	729,498		
Provision for dismantling cost		990	2,280	-	-		
Provision for long-term employee benefits	11	129,270	98,360	33,592	25,109		
Total non-current liabilities		1,018,875	940,843	649,977	754,607		
Total liabilities		2,715,632	2,903,170	1,241,732	1,275,839		

(Unit: Thousand Baht)

Statements of financial position (continued)

As at 30 September 2019

			(Ur	nit: Thousand Baht)
	Consolidated fina	ancial statements	Separate finan	cial statements
	30 September 2019	31 December 2018	30 September 2019	31 December 2018
	(Unaudited	(Audited)	(Unaudited	(Audited)
	but reviewed)		but reviewed)	
Shareholders' equity				
Share capital				
Registered				
500,000,000 ordinary shares of Baht 1 each	500,000	500,000	500,000	500,000
Issued and fully paid				
482,579,640 ordinary shares of Baht 1 each	482,580	482,580	482,580	482,580
Non-controlling interests of subsidiary acquired by				
the Company at price higher than book value	(80,767)	(80,767)	-	-
Non-controlling interest in subsidiary of				
the associated company acquired at price				
lower than book value	1,494	1,494	-	-
Change in the interest in subsidiaries of				
the associated company which did not result				
in a loss of control of the associate	(135,833)	(135,833)	-	-
Capital reserve for share-based payment transactions				
of the associate	41,004	41,071	-	-
Retained earnings				
Appropriated - statutory reserve	50,000	50,000	50,000	50,000
Unappropriated	3,870,479	3,876,971	1,641,016	1,624,483
Other components of shareholders' equity	(248,802)	(62,112)	<u>-</u>	
Total shareholders' equity	3,980,155	4,173,404	2,173,596	2,157,063
Total liabilities and shareholders' equity	6,695,787	7,076,574	3,415,328	3,432,902

The accompanying notes are an integral part of the interim financial statements.

Directors

-

Statements of comprehensive income

For the three-month period ended 30 September 2019

Other income         Dividend income from subsidiaries         5         -         -         36,896           Dividend income from associate         6         -         -         147,953         -           Management income         2         -         -         19,605         19,032           Gain on changes in fair value of biological assets         1,385         976         -         -           Others         27,281         37,623         1,620         2,267           Total revenues         2866,455         1,126,226         245,292         157,673           Expenses         -         -         245,292         157,673           Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         114,057         107,485         49,436         48,699           Total expenses         979,552         1,077,168         97,433         130,991           Profit (loss) before share of profit from         -         -         -         -           income tax expenses         (93,097)         49,058         147,859         26,682           Share of profit from investment in associate         6         166,872         1,165         -			(Unit: Thousa	and Baht, except e	arnings per share exp	pressed in Baht)
Profit or loss:         Revenues           Sales         857,789         1,087,627         76,114         99,476           Other income         Dividend income from subsidiaries         5         -         -         36,890           Dividend income from subsidiaries         5         -         -         36,890           Dividend income from associate         6         -         -         147,953         -           Gain on charges in fair value of biological assets         1,385         976         -         -         36,800           Others         27,281         37,623         1,620         2,260         - <th></th> <th>-</th> <th>Consolidated finance</th> <th>cial statements</th> <th>Separate financia</th> <th>I statements</th>		-	Consolidated finance	cial statements	Separate financia	I statements
Revenues         Sales         857,789         1,087,627         76,114         99,476           Other income         Dividend income from subsidiaries         5         -         -         36,896           Dividend income from subsidiaries         5         -         -         36,896           Dividend income from associate         6         -         147,953         -           Management income         2         -         -         19,605         19,003           Gain on changes in fair value of biological assets         1,385         976         -         -           Others         27,281         37,623         1,620         2,267           Total revenues         286,455         1,126,226         245,292         157,677           Expenses         205 of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         120,492         148,606         -         2,833           Administrative expenses         979,552         1,077,168         97,433         130,997           Profit (loss) before share of profit from         income tax expenses         73,775         50,223         147,859         26,682           Finance cost         (18,086)		<u>Note</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Sales         857,789         1,087,627         76,114         99,478           Other income         Dividend income from subsidiaries         5         -         -         36,896           Dividend income from subsidiaries         5         -         -         36,896           Dividend income from associate         6         -         147,953         -           Management income         2         -         -         19,605         19,035           Gain on changes in fair value of biological assets         1,385         976         -         -           Others         27,281         37,623         1,620         2,267           Total revenues         886,455         1,126,226         245,292         157,673           Expenses         -         -         245,292         157,673           Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         114,057         107,485         49,436         48,691           Total expenses         979,552         1,077,168         97,433         130,991           Profit (loss) before share of profit from         -         -         -         -           Investment in associate <td>Profit or loss:</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Profit or loss:					
Other income         Dividend income from subsidiaries         5         -         -         -         36.896           Dividend income from associate         6         -         -         147,953         -         -         36.896           Dividend income from associate         6         -         -         19,605         19,035         30.935           Gain on changes in fair value of biological assets         1,385         976         -         -         -         19,605         19,035           Gothers         27,281         37,623         1,620         2,267         -         <	Revenues					
Dividend income from subsidiaries         5         -         -         36,899           Dividend income from associate         6         -         147,953         -           Management income         2         -         -         19,605         19,033           Gain on changes in fair value of biological assets         1,385         976         -         -           Others         27,281         37,623         1,620         2,267           Total revenues         886,455         1,126,226         245,292         157,673           Expenses         20,492         148,606         -         2,833           Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         114,057         107,485         49,436         48,699           Total expenses         979,552         1,077,168         97,433         130,997           Profit (loss) before share of profit from         income tax expenses         (93,097)         49,058         147,859         26,682           Share of profit from investment in associate         6         166,872         1,165         -         -           Profit before income tax expenses         73,75         50,223         147	Sales		857,789	1,087,627	76,114	99,478
Dividend income from associate         6         -         147,953           Management income         2         -         19,605         19,035           Gain on changes in fair value of biological assets         1,385         976         -         -           Others         27,281         37,623         1,620         2,265           Total revenues         886,455         1,126,226         245,292         157,673           Expenses         886,455         1,126,226         245,292         157,673           Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         120,492         148,606         -         2,833           Administrative expenses         114,057         107,485         49,436         48,694           Total expenses         979,552         1,077,168         97,433         130,997           Profit (loss) before share of profit from         income tax expenses         (93,097)         49,058         147,859         26,682           Share of profit from investment in associate         6         166,872         1,165         -         -           Profit before income tax expenses         73,775         50,223         147,859         26,	Other income					
Management income         2         -         19,605         19,035           Gain on changes in fair value of biological assets         1,385         976         - <td>Dividend income from subsidiaries</td> <td>5</td> <td>-</td> <td>-</td> <td>-</td> <td>36,896</td>	Dividend income from subsidiaries	5	-	-	-	36,896
Gain on changes in fair value of biological assets       1,385       976       -         Others       27,281       37,623       1,620       2,267         Total revenues       886,455       1,126,226       245,292       157,673         Expenses       2       120,492       148,606       -       2,833         Cost of sales       745,003       821,077       47,997       79,467         Selling and distribution expenses       120,492       148,606       -       2,833         Administrative expenses       1979,552       1,077,168       974,333       130,991         Total expenses       979,552       1,077,168       974,433       130,991         Profit (loss) before share of profit from       income tax expenses       (93,097)       49,058       147,859       26,682         Share of profit from investment in associate       6       166,872       1,165       -       -         Profit before finance cost and income tax expenses       73,775       50,223       147,859       26,682         Finance cost       (18,086)       (16,294)       (10,849)       (8,927         Profit before income tax expenses       55,689       33,929       137,010       17,763         Income tax benefit (expen	Dividend income from associate	6	-	-	147,953	-
Others         27,281         37,623         1,620         2,267           Total revenues         886,455         1,126,226         245,292         157,673           Expenses         2         2         37,623         1,620         2,266           Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         120,492         148,606         -         2,833           Administrative expenses         979,552         1,077,168         97,433         130,991           Profit (loss) before share of profit from         investment in associate, finance cost and         141,057         1,077,168         97,433         130,991           Profit before finance cost and         (93,097)         49,058         147,859         26,682           Share of profit from investment in associate         6         166,872         1,165         -           Profit before finance cost and income tax expenses         73,775         50,223         147,859         26,682           Finance cost         (18,086)         (16,294)         (10,849)         (8,927)           Profit before income tax expenses         55,689         33,929         137,101         17,761           Income tax benefit (expenses)	Management income	2	-	-	19,605	19,032
Total revenues         886,455         1,126,226         245,292         157,673           Expenses         Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         120,492         148,606         -         2,833           Administrative expenses         114,057         107,485         49,436         48,697           Total expenses         979,552         1,077,168         97,433         130,997           Profit (loss) before share of profit from         979,552         1,077,168         97,433         130,997           Investment in associate, finance cost and         6         166,872         1,165         -         -           Profit before finance cost and income tax expenses         73,775         50,223         147,859         26,682           Finance cost         (18,086)         (16,294)         (10,849)         (8,927)           Profit before income tax expenses         55,689         33,929         137,010         17,761           Income tax benefit (expenses)         12         3,675         (4,069)         91         379           Profit for the period         59,364         29,860         137,101         18,140         18,140           Other	Gain on changes in fair value of biological assets		1,385	976	-	-
Expenses         745,003         821,077         47,997         79,467           Selling and distribution expenses         120,492         148,606         -         2,833           Administrative expenses         114,057         107,485         49,436         48,691           Total expenses         979,552         1,077,168         97,433         130,991           Profit (loss) before share of profit from investment in associate, finance cost and income tax expenses         (93,097)         49,058         147,859         26,682           Share of profit from investment in associate         6         166,872         1,165         -         -           Profit before finance cost and income tax expenses         73,775         50,223         147,859         26,682           Finance cost         (18,086)         (16,294)         (10,849)         (8,927)           Profit before income tax expenses         55,689         33,929         137,010         17,761           Income tax benefit (expenses)         12         3,675         (4,069)         91         375           Profit for the period         59,364         29,860         137,101         18,140           Other comprehensive income to be reclassified to profit or loss in subsequent periods:         51,369         (74,313)	Others	-	27,281	37,623	1,620	2,267
Cost of sales         745,003         821,077         47,997         79,467           Selling and distribution expenses         120,492         148,606         2,833           Administrative expenses         114,057         107,485         49,436         48,691           Total expenses         979,552         1,077,168         97,433         130,991           Profit (loss) before share of profit from         979,552         1,077,168         97,433         130,991           Income tax expenses         (93,097)         49,058         147,859         26,682           Share of profit from investment in associate         6         166,872         1,165         -           Profit before finance cost and income tax expenses         73,775         50,223         147,859         26,682           Finance cost         (18,086)         (16,294)         (10,849)         (8,927)           Profit before income tax expenses         55,689         33,929         137,010         17,761           Income tax benefit (expenses)         12         3,675         (4,069)         91         375           Profit for the period         59,364         29,860         137,101         18,140           Other comprehensive income to be reclassified         12         3,675	Total revenues	-	886,455	1,126,226	245,292	157,673
Selling and distribution expenses       120,492       148,606       -       2,833         Administrative expenses       114,057       107,485       49,436       48,694         Total expenses       979,552       1,077,168       97,433       130,944         Profit (loss) before share of profit from       979,552       1,077,168       97,433       130,944         income tax expenses       (93,097)       49,058       147,859       26,682         Share of profit from investment in associate       6       166,872       1,165       -         Profit before finance cost and income tax expenses       73,775       50,223       147,859       26,682         Finance cost       (18,086)       (16,294)       (10,849)       (8,927)         Profit before income tax expenses       55,689       33,929       137,010       17,761         Income tax benefit (expenses)       12       3,675       (4,069)       91       375         Profit for the period       59,364       29,860       137,101       18,140         Other comprehensive income:       Cther comprehensive income to be reclassified       10,136       -       -       -         Share of comprehensive income in associate       (6,136)       (74,313)       -       - </td <td>Expenses</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Expenses					
Administrative expenses       114,057       107,485       49,436       48,691         Total expenses       979,552       1,077,168       97,433       130,991         Profit (loss) before share of profit from       income tax expenses       (93,097)       49,058       147,859       26,682         Share of profit from investment in associate       6       166,872       1,165       -       -         Profit before finance cost and income tax expenses       73,775       50,223       147,859       26,682         Finance cost       (18,086)       (16,294)       (10,849)       (8,924)         Profit before income tax expenses       55,689       33,929       137,010       17,761         Income tax benefit (expenses)       12       3,675       (4,069)       91       372         Profit for the period       59,364       29,860       137,101       18,140         Other comprehensive income to be reclassified       to profit or loss in subsequent periods:       5       5       5       5       137,101       18,140         Other comprehensive income in associate       (6,136)       (74,313)       -       -       -       -	Cost of sales		745,003	821,077	47,997	79,467
Total expenses979,5521,077,16897,433130,994Profit (loss) before share of profit from investment in associate, finance cost and income tax expenses(93,097)49,058147,85926,682Share of profit from investment in associate6166,8721,165Profit before finance cost and income tax expenses73,77550,223147,85926,682Finance cost(18,086)(16,294)(10,849)(8,927)Profit before income tax expenses55,68933,929137,01017,761Income tax benefit (expenses)123,675(4,069)91375Profit for the period59,36429,860137,10118,140Other comprehensive income:Cother comprehensive income to be reclassified to profit or loss in subsequent periods:(6,136)(74,313)	Selling and distribution expenses		120,492	148,606	-	2,833
Profit (loss) before share of profit from investment in associate, finance cost and income tax expenses(93,097)49,058147,85926,682Share of profit from investment in associate6166,8721,165Profit before finance cost and income tax expenses73,77550,223147,85926,682Finance cost(18,086)(16,294)(10,849)(8,921Profit before income tax expenses55,68933,929137,01017,761Income tax benefit (expenses)123,675(4,069)91375Profit for the period59,36429,860137,10118,140Other comprehensive income:Other comprehensive income to be reclassified to profit or loss in subsequent periods:(6,136)(74,313)	Administrative expenses	-	114,057	107,485	49,436	48,691
investment in associate, finance cost andincome tax expenses(93,097)49,058147,85926,682Share of profit from investment in associate6166,8721,165Profit before finance cost and income tax expenses73,77550,223147,85926,682Finance cost(18,086)(16,294)(10,849)(8,924)Profit before income tax expenses55,68933,929137,01017,764Income tax benefit (expenses)123,675(4,069)91379Profit for the period59,36429,860137,10118,140Other comprehensive income:000137,10118,140Other comprehensive income in associate(6,136)(74,313)	Total expenses	-	979,552	1,077,168	97,433	130,991
income tax expenses       (93,097)       49,058       147,859       26,682         Share of profit from investment in associate       6       166,872       1,165       - <t< td=""><td>Profit (loss) before share of profit from</td><td></td><td></td><td></td><td></td><td></td></t<>	Profit (loss) before share of profit from					
Share of profit from investment in associate6166,8721,165Profit before finance cost and income tax expenses73,77550,223147,85926,682Finance cost(18,086)(16,294)(10,849)(8,924)Profit before income tax expenses55,68933,929137,01017,764Income tax benefit (expenses)123,675(4,069)91375Profit for the period59,36429,860137,10118,140Other comprehensive income:Other comprehensive income to be reclassified to profit or loss in subsequent periods:(6,136)(74,313)	investment in associate, finance cost and					
Profit before finance cost and income tax expenses       73,775       50,223       147,859       26,682         Finance cost       (18,086)       (16,294)       (10,849)       (8,921         Profit before income tax expenses       55,689       33,929       137,010       17,761         Income tax benefit (expenses)       12       3,675       (4,069)       91       379         Profit for the period       59,364       29,860       137,101       18,140         Other comprehensive income:       0ther comprehensive income to be reclassified to profit or loss in subsequent periods:       (6,136)       (74,313)	income tax expenses		(93,097)	49,058	147,859	26,682
Finance cost       (18,086)       (16,294)       (10,849)       (8,924)         Profit before income tax expenses       55,689       33,929       137,010       17,764         Income tax benefit (expenses)       12       3,675       (4,069)       91       375         Profit for the period       59,364       29,860       137,101       18,140         Other comprehensive income:       Other comprehensive income to be reclassified to profit or loss in subsequent periods:       (6,136)       (74,313)       -       -	Share of profit from investment in associate	6	166,872	1,165		-
Profit before income tax expenses55,68933,929137,01017,761Income tax benefit (expenses)123,675(4,069)91375Profit for the period59,36429,860137,10118,140Other comprehensive income:00000Other comprehensive income to be reclassified to profit or loss in subsequent periods:6,136)(74,313)	Profit before finance cost and income tax expenses		73,775	50,223	147,859	26,682
Income tax benefit (expenses)123,675(4,069)91379Profit for the period59,36429,860137,10118,140Other comprehensive income:00000Other comprehensive income to be reclassified to profit or loss in subsequent periods:0000Share of comprehensive income in associate(6,136)(74,313)-0	Finance cost	-	(18,086)	(16,294)	(10,849)	(8,921)
Profit for the period       59,364       29,860       137,101       18,140         Other comprehensive income:       0	Profit before income tax expenses		55,689	33,929	137,010	17,761
Other comprehensive income:         Other comprehensive income to be reclassified         to profit or loss in subsequent periods:         Share of comprehensive income in associate         (6,136)       (74,313)	Income tax benefit (expenses)	12	3,675	(4,069)	91	379
Other comprehensive income to be reclassified         to profit or loss in subsequent periods:         Share of comprehensive income in associate       (6,136)       (74,313)	Profit for the period	-	59,364	29,860	137,101	18,140
to profit or loss in subsequent periods: Share of comprehensive income in associate (6,136) (74,313)	Other comprehensive income:					
Share of comprehensive income in associate (6,136) (74,313)	Other comprehensive income to be reclassified					
	to profit or loss in subsequent periods:					
	Share of comprehensive income in associate	_	(6,136)	(74,313)	<u> </u>	
	Other comprehensive income for the period	-	(6,136)	(74,313)		-
		_				
Total comprehensive income for the period         53,228         (44,453)         137,101         18,140	Total comprehensive income for the period	-	53,228	(44,453)	137,101	18,140

## Statements of comprehensive income (continued)

### For the three-month period ended 30 September 2019

		(Unit: Thousand Baht, except earnings per share expressed in Baht)			
		Consolidated fina	ancial statements	Separate financial statement	
	<u>Note</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Profit attributable to:					
Equity holders of the Company		59,364	29,860	137,101	18,140
Total comprehensive income attributable to:					
Equity holders of the Company		53,228	(44,453)	137,101	18,140
Earnings per share (Baht)					
Basic earnings per share					
Profit attributable to equity holders of the Company		0.12	0.06	0.28	0.04

Statements of comprehensive income

For the nine-month period ended 30 September 2019

		(Unit: Thousand Baht, except earnings per share expressed in Baht)					
		Consolidated finance	cial statements	Separate financia	I statements		
	<u>Note</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>		
Profit or loss:							
Revenues							
Sales		2,776,608	3,124,915	278,172	278,144		
Other income							
Dividend income from subsidiaries	5	-	-	19,800	64,288		
Dividend income from associate	6	-	-	258,917	332,893		
Management income	2	-	-	53,129	57,096		
Gain on changes in fair value of biological assets		990	-	-	-		
Others		106,656	94,666	12,660	8,332		
Total revenues		2,884,254	3,219,581	622,678	740,753		
Expenses							
Cost of sales		2,480,980	2,458,740	195,864	198,442		
Selling and distribution expenses		364,398	465,822	5	14,031		
Administrative expenses		342,317	333,996	142,130	133,090		
Other expenses							
Reversal of impairment loss on machinery		-	(29,000)	-	-		
Loss on changes in fair value of biological assets		<u> </u>	1,799	<u> </u>	-		
Total expenses		3,187,695	3,231,357	337,999	345,563		
Profit (loss) before share of profit from							
investment in associate, finance cost and							
income tax expenses		(303,441)	(11,776)	284,679	395,190		
Share of profit from investment in associate	6	582,530	101,684	<u> </u>	-		
Profit before finance cost and income tax expenses		279,089	89,908	284,679	395,190		
Finance cost		(53,187)	(40,573)	(33,391)	(20,845)		
Profit before income tax expenses		225,902	49,335	251,288	374,345		
Income tax benefit (expenses)	12	4,067	(39,716)	1,706	(1,125)		
Profit for the period		229,969	9,619	252,994	373,220		
Other comprehensive income:							
Other comprehensive income to be reclassified							
to profit or loss in subsequent periods:							
Share of comprehensive income in associate		(186,690)	(64,475)	<u> </u>			
Other comprehensive income for the period		(186,690)	(64,475)				
Total comprehensive income for the period		43,279	(54,856)	252,994	373,220		

## Statements of comprehensive income (continued)

### For the nine-month period ended 30 September 2019

		(Unit: Thousand Baht, except earnings per share expressed in Baht)			
		Consolidated fina	ancial statements	Separate finance	cial statements
	<u>Note</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Profit attributable to:					
Equity holders of the Company		229,969	9,619	252,994	373,220
Total comprehensive income attributable to:					
Equity holders of the Company		43,279	(54,856)	252,994	373,220
Earnings per share (Baht)					
Basic earnings per share					
Profit attributable to equity holders of the Company		0.48	0.02	0.52	0.77

#### Statements of changes in shareholders' equity

For the nine-month period ended 30 September 2019

				(	Consolidated finar	icial statements			·	,
		Non-controlling	Non-controlling	Change in the interest			-	Other component of share	nolder's equity	
		interests of	interest of subsidiary	in subsidiaries of	Capital reserve			Other		
		subsidiary acquired	of the associated	the associated company	for share-based		-	comprehensive income	Total other	
	Issued and	by the Company	company acquired	which did not result	payment	Retained	earnings	Share of	components of	Total
	paid-up	at price higher	at price lower	in a loss of control	transactions of	Appropriated -		comprehensive income	shareholders'	shareholders'
	share capital	than book value	than book value	of the associate	the associate	statutory reserve	_Unappropriated	in associate	equity	equity
Balance as at 1 January 2018	482,580	(80,767)	1,494	(135,833)	36,872	50,000	4,155,881	(139,611)	(139,611)	4,370,616
Profit for the period	-	-	-	-	-	-	9,619	-	-	9,619
Other comprehensive income for the period								(64,475)	(64,475)	(64,475)
Total comprehensive income for the period	-	-	-	-	-	-	9,619	(64,475)	(64,475)	(54,856)
Share-based payment transactions of the associate	-	-	-	-	3,009	-	-	-	-	3,009
Dividend paid (Note 13)							(241,287)	<u> </u>		(241,287)
Balance as at 30 September 2018	482,580	(80,767)	1,494	(135,833)	39,881	50,000	3,924,213	(204,086)	(204,086)	4,077,482
Balance as at 1 January 2019	482,580	(80,767)	1,494	(135,833)	41,071	50,000	3,876,971	(62,112)	(62,112)	4,173,404
Profit for the period	-	-	-	-	-	-	229,969	-	-	229,969
Other comprehensive income for the period								(186,690)	(186,690)	(186,690)
Total comprehensive income for the period	-	-	-	-	-	-	229,969	(186,690)	(186,690)	43,279
Share-based payment transactions of the associate	-	-	-	-	(67)	-	-	-	-	(67)
Dividend paid (Note 13)							(236,461)	<u> </u>	-	(236,461)
Balance as at 30 September 2019	482,580	(80,767)	1,494	(135,833)	41,004	50,000	3,870,479	(248,802)	(248,802)	3,980,155

The accompanying notes are an integral part of the interim financial statements.

(Unaudited but reviewed)

(Unit: Thousand Baht)

-

(Unaudited but reviewed)

Tipco Foods Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity (continued)

For the nine-month period ended 30 September 2019

(Unit: Thousand Baht)

-

	Separate financial statements						
	-	Retained e	arnings				
	Issued and paid-up	Appropriated -		Total			
	share capital	statutory reserve	Unappropriated	shareholders'equity			
Balance as at 1 January 2018	482,580	50,000	1,513,204	2,045,784			
Profit for the period	-	-	373,220	373,220			
Other comprehensive income for the period	<u> </u>	<u> </u>	-				
Total comprehensive income for the period	-	-	373,220	373,220			
Dividend paid (Note 13)	<u> </u>	<u> </u>	(241,287)	(241,287)			
Balance as at 30 September 2018	482,580	50,000	1,645,137	2,177,717			
Balance as at 1 January 2019	482,580	50,000	1,624,483	2,157,063			
Profit for the period	-	-	252,994	252,994			
Other comprehensive income for the period	<u> </u>		-				
Total comprehensive income for the period	-	-	252,994	252,994			
Dividend paid (Note 13)	<u> </u>		(236,461)	(236,461)			
Balance as at 30 September 2019	482,580	50,000	1,641,016	2,173,596			

### Cash flow statements

## For the nine-month period ended 30 September 2019

Consolidated TermsSeparate Terms20192018201920192019201920192019Cash flows from operating activities:252.024.0.30251.28Adjustments to recordie profil before income tax255.024.0.30255.02Depreciation and montisation170.01205.4224.0.7.05355.03Advoarce for doubtil accord (reversal)0.0102.022(56.42)4.0.7.01(.0.10)Reduction of cost of inventories to net realisable value (reversal)20.022(56.42)4.0.7.1(.0.10)(Goin) loss on danges in fair value of biological assets0.0001.7.09(.0.10)(.0.10)(Gain) loss on changes in fair value of interest and equipment16.0.7(.0.000(.0.10)(.0.10)(Gain) loss on changes in fair value of interest and equipment16.0.7(.0.20)(.0.10)(.0.10)(Gain) loss on stales and wither-off of property. Jent and equipment16.0.7(.0.20)(.0.10)(.0.10)(Gain) loss on stales and wither-off of property. Jent and equipment16.0.7(.0.20)(.0.10)(.0.10)(Gain) loss on stales and wither-off of property. Jent and equipment16.0.7(.0.20)(.0.20)(.0.20)Provision for dange in fair value of interest and equipment16.0.7(.0.20)(.0.20)(.0.20)Reversal of impainment loss on machinery.0.1.0.1(.0.20)(.0.20)(.0.20)(.0.20)Dividend from subsidianes.0.20.0.20.0.20(.0.20)				(Unit: T	housand Baht)
Cash flows from operating activities:         225,902         49,335         251,288         374,345           Adjustments to reconcile profit before income tax         5         <		Consolidated finan	cial statements	Separate financia	l statements
Profit before income tax         225,002         49,335         251,288         374,345           Adjustments to reconcile profit before income tax              574,345           Adjustments to reconcile profit before income tax            575,359           Depreciation and amortisation         187,913         205,422         47,725         55,359           Allowance for doubtful account (reversal)         20,922         (56,442)         887         (255)           Loss from stock destruction         16,020         4,755         1,721         -         -         (Gain) loss on changes in fair value of forward exchange contracts         4,219         (1,008)         -         (1)         (Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (628)         (628)         (638)         0.67         (0.67)         (0.65)         (10)         (50)         -         (10)         (50)         -         (10)         (50)         -         (28)         (28)         (28)         (28)         (28)         (28)         (28)         (28)         (28)         (28)         (28)         -         (28)         (28)         (28)         (28)         28)		<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Adjustments to reconcile profit before income tax         to net cash provided by (paid from) operating activities:         Depreciation and amortisation       187,913       205,422       47,725       35,539         Allowance for doubtful account (reversal)       20,922       (26,642)       887       (255)         Loss from tock destruction       16,020       47,755       1,721       -         (Gain) loss on changes in fair value of biological assets       (990)       1,799       -       -         (Gain) loss on exchange       (924)       3       19       162         (Gain) loss on changes in fair value of forward exchange contracts       4,219       (1,008)       -       (1)         (Gain) loss on changes in fair value of intergible assets       838       28       -       (28)         (Gain) loss on machinery       -       (28,000)       -       -         (Gain) loss on sales and withen-off of intangible assets       838       28       -       (28)         Provision for ding-term employee benefits       34,803       7,714       8,823       2,268         Dividend income from subcilaties       -       (19,800)       (64,289)       0.1         Dividend income from subcilaties       -       (252,917)       (332,859)       20,747	Cash flows from operating activities:				
Ite onet cash provided by (paid from) operating activities:           Depreciation and amortisation         187,913         205,422         47,725         35,539           Allowance for doubtif account (reversal)         (501)         28         -         -           Reduction of cost of inventories to net realisable value (reversal)         20,922         (56,442)         887         (255)           (Gain) loss on changes in fair value of biological assets         (990)         1,799         -         -           (Gain) loss on changes in fair value of inverser tate swap contracts         4,219         (10,08)         -         (0)           (Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (628)           (Gain) loss on sales and written-off of propery, plant and equipment         16,537         (1,255)         (37)         105           (Gain) loss on sales and written-off of intangible assets         838         28         -         (28)           Provision for dispatifications         -         (29,000)         -         -           Provision for dispatifications         -         (28,017)         (332,839)           Share of profit from investment in associate         (682,530)         (101,684)         -         -           Interest	Profit before income tax	225,902	49,335	251,288	374,345
Depreciation and amortisation         187,913         205,422         47,725         35,539           Allowance for doubful account (reversal)         (501)         28         -         -           Reduction of cost of inventories to net realisable value (reversal)         20,922         (56,442)         887         (255)           Loss from stock destruction         16,020         4.755         1.721         -         -           (Gain) loss on changes in fair value of biological assets         (990)         1.799         -         -         -           (Gain) loss on changes in fair value of interest rate swap contract         2.64         (628)         2.64         (628)         (637)         105         (10)           (Gain) loss on sales and written-off or frangible assets         8.38         28         -         (28)           Reversal of inpairment loss on machinery         -         (29,000)         -         -         -           Provision for long-term employee benefits         34,803         7.714         8.823         2.2681           Provision for insestment in associate         -         -         (19,800)         (64.289)           Dividend income from subsidiaries         -         -         (28,917)         (32.8693)           Interest income	Adjustments to reconcile profit before income tax				
Allowance for doubtful account (reversal)         (501)         28         .           Reduction of cost of inventories to net realisable value (reversal)         20,922         (56,442)         887         (255)           Loss from stock destruction         16,020         4,755         1,721         .           (Gain) loss on changes in fair value of biological assets         (990)         1,799         .         .           (Gain) loss on changes in fair value of forward exchange contracts         4,219         (1,008)         .         (1)           (Gain) loss on changes in fair value of forward exchange contracts         4,219         (1,025)         (87)         105           (Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (628)           (Gain) loss on sales and written-off of property, plant and equipment         16,537         (1,255)         (87)         105           (Gain) loss on sales and written-off of intangible assets         838         28         .         (28)           Reversal of impairment loss on machinery         .         (29,000)         .         .           Provision for dismantling cost         209         120         .         .           Dividend income from subsidiaries         .         .         (19,800	to net cash provided by (paid from) operating activities:				
Reduction of cost of inventories to net realisable value (reversal)         20.922         (56.442)         887         (255)           Loss from stock destruction         16,020         4.755         1,721         -           (Gain) loss on changes in fair value of biological assets         (990)         1,799         -         -           Urrealised (gain) loss on changes in fair value of forward exchange contracts         4.219         (1008)         -         (1)           (Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (628)           (Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (628)           (Gain) loss on sales and written-off of property, plant and equipment         16,57         (1,255)         (87)         1005           (Gain) loss on sales and written-off of intangible assets         838         28         -         (28)           Reversal of impairment loss on machinery         -         (29,000)         -         -           Provision from associate         209         120         -         -           Dividend income from associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73) <t< td=""><td>Depreciation and amortisation</td><td>187,913</td><td>205,422</td><td>47,725</td><td>35,539</td></t<>	Depreciation and amortisation	187,913	205,422	47,725	35,539
Loss from stock destruction         16,020         4,755         1,721           (Gain) loss on changes in fair value of biological assets         (990)         1,799         -           Unrealised (gain) loss on exchange         (924)         3         19         162           (Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (629)           (Gain) loss on sales and written-off of property, plant and equipment         16,537         (1265)         (67)         105           (Gain) loss on sales and written-off of intengible assets         838         28         -         (28)           (Gain) loss on sales and written-off of intengible assets         34,803         7,714         8,823         2,268           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Dividend income from subsidiaries         -         -         (19,800)         (64,289)           Dividend income from subsidiaries         -         -         (19,800)         20,747           Proful (rom investment in associate         -         -         -         -           operating assets	Allowance for doubtful account (reversal)	(501)	28	-	-
(Gain) loss on changes in fair value of biological assets         (990)         1.799         -         -           Unrealised (gain) loss on exchange         (924)         3         19         162           (Gain) loss on exchange in fair value of forward exchange contracts         4.219         (1.008)         -         (1)           (Gain) loss on enales and writter-off of property, plant and equipment         16.537         (1.265)         (87)         105           (Gain) loss on sales and writter-off of property, plant and equipment         16.537         (1.265)         (87)         105           (Gain) loss on sales and writter-off of property, plant and equipment         16.537         (1.265)         (87)         105           (Gain) loss on sales and writter-off of property, plant and equipment         16.537         (1.265)         (87)         105           (Gain) loss on sales and writter-off of property, plant and equipment         16.537         (1.265)         (87)         105           (Gain) loss on sales and writter-off of property, plant and equipment         16.537         (1.265)         (87)         2.268           Provision for olg-term employee benefits         34.803         7.714         8.823         2.268           Dividend income from associate         (582,530)         (101.684)         -         -	Reduction of cost of inventories to net realisable value (reversal)	20,922	(56,442)	887	(255)
Unrealised (gain) loss on exchange         (924)         3         19         162           (Gain) loss on exchanges in fair value of forward exchange contracts         4,219         (1,008)         -         (1)           (Gain) loss on exlanges in fair value of interest rate swap contract         264         (628)         264         (628)           (Gain) loss on sales and written-off of property, plant and equipment         16,537         (1,265)         (87)         105           (Gain) loss on sales and written-off of intangible assets         838         28         -         (28)           Reversal of impairment loss on machinery         -         (29,000)         -         -           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         -         -           Dividend income from subsidiaries         -         (19,800)         (64,289)           Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) fro	Loss from stock destruction	16,020	4,755	1,721	-
(Gain) loss on changes in fair value of forward exchange contracts         4.219         (1,008)         -         (1)           (Gain) loss on changes in fair value of interest rate swap contract         284         (628)         264         (628)           (Gain) loss on sales and written-off of property, plant and equipment         16,537         (1,265)         (87)         105           (Gain) loss on sales and written-off of intangible assets         838         28         -         (28)           Reversal of impairment loss on machinery         -         (29,000)         -         -           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         -         -           Dividend income from subsidiaries         -         (19,800)         (64,288)           Dividend income from subsidiaries         -         (258,917)         (332,893)           Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activi	(Gain) loss on changes in fair value of biological assets	(990)	1,799	-	-
(Gain) loss on changes in fair value of interest rate swap contract         264         (628)         264         (628)           (Gain) loss on sales and written-off of property, plant and equipment         16.537         (1,265)         (87)         105           (Gain) loss on sales and written-off of intangible assets         838         28         -         (28)           Reversal of impairment loss on machinery         -         (29,000)         -         -           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         -         -           Dividend income from subsidiaries         -         (19,800)         (64,288)           Dividend income from subsidiaries         -         -         (258,917)         (332,893)           Share of profit from investment in associate         -         -         (19,800)         (64,287)           Interest income         (63)         (73)         (2,602)         (1,287)           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52.026         40,450         32,359         20,747           Profit (loss) from operating assets         (1,638) <td>Unrealised (gain) loss on exchange</td> <td>(924)</td> <td>3</td> <td>19</td> <td>162</td>	Unrealised (gain) loss on exchange	(924)	3	19	162
(Gain) loss on sales and written-off of property, plant and equipment         16,537         (1,265)         (87)         105           (Gain) loss on sales and written-off of intangible assets         838         28         -         (28)           Reversal of impairment loss on machinery         -         (29,000)         -         -           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         -         -           Dividend income from subsidiaries         -         (19,800)         (64,288)           Dividend income from subsidiaries         -         (258,917)         (332,893)           Share of profit from investment in associate         (582,530)         (101,684)         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating assets         119,554         61,680         33,786           (Increase) decrease in operating assets         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (13,97)         (14,194)	(Gain) loss on changes in fair value of forward exchange contracts	4,219	(1,008)	-	(1)
(Gain) loss on sales and written-off of intangible assets         838         28         .         (28)           Reversal of impairment loss on machinery         .         (29,000)         .         .           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         .         .           Dividend income from subsidiaries         .         .         (19,800)         (64,288)           Dividend income from associate         .         .         .         .         .           Dividend income from associate         .         .         .         .         .         .           Interest income         .         .         .         .         .         .         .         .           operating assets and liabilities         . <td>(Gain) loss on changes in fair value of interest rate swap contract</td> <td>264</td> <td>(628)</td> <td>264</td> <td>(628)</td>	(Gain) loss on changes in fair value of interest rate swap contract	264	(628)	264	(628)
Reversal of impairment loss on machinery         .         .         .           Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         -         -           Dividend income from subsidiaries         -         .	(Gain) loss on sales and written-off of property, plant and equipment	16,537	(1,265)	(87)	105
Provision for long-term employee benefits         34,803         7,714         8,823         2,268           Provision for dismantling cost         209         120         -         -           Dividend income from subsidiaries         -         -         (19,800)         (64,288)           Dividend income from associate         -         -         (258,917)         (332,893)           Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other non-current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (21,	(Gain) loss on sales and written-off of intangible assets	838	28	-	(28)
Provision for dismantling cost         209         120         -           Dividend income from subsidiaries         -         (19,800)         (64,288)           Dividend income from associate         -         (258,917)         (332,893)           Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         (25,355)         119,554         61,680         (5,124)           Inventories         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (6)         17,514           Other non-current assets         (233,324)         (178,238)         (14,969)         (38,850)           Other current liabilities         (21,919)         47,212         11,614         14,461 <td>Reversal of impairment loss on machinery</td> <td>-</td> <td>(29,000)</td> <td>-</td> <td>-</td>	Reversal of impairment loss on machinery	-	(29,000)	-	-
Dividend income from subsidiaries         -         (19,800)         (64,288)           Dividend income from associate         -         (258,917)         (332,893)           Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         (162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         (7,581)         (34,520)         (357)         935           Increase (decrease) in operating liabilities         (23,324)         (178,238)         (14,969)         (38,850)           Other non-current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)	Provision for long-term employee benefits	34,803	7,714	8,823	2,268
Dividend income from associate         -         -         (258,917)         (332,893)           Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (21,919)         47,212         11,614         14,461           Other non-current li	Provision for dismantling cost	209	120	-	-
Share of profit from investment in associate         (582,530)         (101,684)         -         -           Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         (25,355)         119,554         61,680         (5,124)           Inventories         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         1         14,461         14,461           Other non-current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)         400         -         -           Cash paid for long-term employee benefits         (3,893)         - </td <td>Dividend income from subsidiaries</td> <td>-</td> <td>-</td> <td>(19,800)</td> <td>(64,288)</td>	Dividend income from subsidiaries	-	-	(19,800)	(64,288)
Interest income         (63)         (73)         (2,602)         (1,287)           Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         1         14,969         (38,850)           Other current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)         400         -         -           Other non-current liabilities         (3,893)         -         (340)         -	Dividend income from associate	-	-	(258,917)	(332,893)
Interest expenses         52,026         40,450         32,359         20,747           Profit (loss) from operating activities before changes in operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         (233,324)         (17,8,238)         (14,969)         (38,850)           Other current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)         400         -         -           Cash paid for long-term employee benefits         (3,893)         -         (340)         -	Share of profit from investment in associate	(582,530)	(101,684)	-	-
Profit (loss) from operating activities before changes in         operating assets and liabilities       (25,355)       119,554       61,680       33,786         (Increase) decrease in operating assets       162,266       57,373       16,380       (5,124)         Inventories       194,918       (11,554)       (1,397)       (14,194)         Other current assets       (7,581)       (34,520)       (8)       17,514         Other non-current assets       1,845       (29,210)       (357)       935         Increase (decrease) in operating liabilities       (23,324)       (178,238)       (14,969)       (38,850)         Other current liabilities       (21,919)       47,212       11,614       14,461         Other non-current liabilities       (1,498)       400       -       -         Cash paid for long-term employee benefits       (3,893)       -       (340)       -	Interest income	(63)	(73)	(2,602)	(1,287)
operating assets and liabilities         (25,355)         119,554         61,680         33,786           (Increase) decrease in operating assets         162,266         57,373         16,380         (5,124)           Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         (233,324)         (178,238)         (14,969)         (38,850)           Other current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)         400         -         -           Cash paid for long-term employee benefits         (3,893)          (340)         -	Interest expenses	52,026	40,450	32,359	20,747
(Increase) decrease in operating assets         Trade and other receivables       162,266       57,373       16,380       (5,124)         Inventories       194,918       (11,554)       (1,397)       (14,194)         Other current assets       (7,581)       (34,520)       (8)       17,514         Other non-current assets       1,845       (29,210)       (357)       935         Increase (decrease) in operating liabilities       1       14,969)       (38,850)         Other current liabilities       (233,324)       (178,238)       (14,969)       (38,850)         Other current liabilities       (21,919)       47,212       11,614       14,461         Other non-current liabilities       (1,498)       400       -       -         Cash paid for long-term employee benefits       (3,893)       -       (340)       -	Profit (loss) from operating activities before changes in				
Trade and other receivables       162,266       57,373       16,380       (5,124)         Inventories       194,918       (11,554)       (1,397)       (14,194)         Other current assets       (7,581)       (34,520)       (8)       17,514         Other non-current assets       1,845       (29,210)       (357)       935         Increase (decrease) in operating liabilities       Trade and other payables       (178,238)       (14,969)       (38,850)         Other current liabilities       (21,919)       47,212       11,614       14,461         Other non-current liabilities       (1,498)       400       -       -         Cash paid for long-term employee benefits       (3,893)        (340)       -	operating assets and liabilities	(25,355)	119,554	61,680	33,786
Inventories         194,918         (11,554)         (1,397)         (14,194)           Other current assets         (7,581)         (34,520)         (8)         17,514           Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         1         17,523         (14,969)         (38,850)           Other current liabilities         233,324)         (178,238)         (14,969)         (38,850)           Other current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)         400         -         -           Cash paid for long-term employee benefits         (3,893)         -         (340)         -	(Increase) decrease in operating assets				
Other current assets       (7,581)       (34,520)       (8)       17,514         Other non-current assets       1,845       (29,210)       (357)       935         Increase (decrease) in operating liabilities       233,324)       (178,238)       (14,969)       (38,850)         Other current liabilities       (21,919)       47,212       11,614       14,461         Other non-current liabilities       (1,498)       400       -       -         Cash paid for long-term employee benefits       (3,893)	Trade and other receivables	162,266	57,373	16,380	(5,124)
Other non-current assets         1,845         (29,210)         (357)         935           Increase (decrease) in operating liabilities         (233,324)         (178,238)         (14,969)         (38,850)           Other current liabilities         (21,919)         47,212         11,614         14,461           Other non-current liabilities         (1,498)         400         -         -           Cash paid for long-term employee benefits         (3,893)         -         (340)         -	Inventories	194,918	(11,554)	(1,397)	(14,194)
Increase (decrease) in operating liabilities(233,324)(178,238)(14,969)(38,850)Other current liabilities(21,919)47,21211,61414,461Other non-current liabilities(1,498)400Cash paid for long-term employee benefits(3,893)(340)-	Other current assets	(7,581)	(34,520)	(8)	17,514
Trade and other payables       (233,324)       (178,238)       (14,969)       (38,850)         Other current liabilities       (21,919)       47,212       11,614       14,461         Other non-current liabilities       (1,498)       400       -       -         Cash paid for long-term employee benefits       (3,893)       -       (340)       -	Other non-current assets	1,845	(29,210)	(357)	935
Other current liabilities(21,919)47,21211,61414,461Other non-current liabilities(1,498)400Cash paid for long-term employee benefits(3,893)-(340)-	Increase (decrease) in operating liabilities				
Other non-current liabilities       (1,498)       400       -       -         Cash paid for long-term employee benefits       (3,893)       -       (340)       -	Trade and other payables	(233,324)	(178,238)	(14,969)	(38,850)
Cash paid for long-term employee benefits (3,893) - (340) -	Other current liabilities	(21,919)	47,212	11,614	14,461
	Other non-current liabilities	(1,498)	400	-	-
Cash flows from (used in) operating activities 65.459 (28.983) 72.603 8.528	Cash paid for long-term employee benefits	(3,893)		(340)	-
	Cash flows from (used in) operating activities	65,459	(28,983)	72,603	8,528
Cash paid for interest expenses (52,343) (40,324) (32,424) (20,641)	Cash paid for interest expenses	(52,343)	(40,324)	(32,424)	(20,641)
Cash paid for corporate income tax (17,821) (39,460) (1,637) (1,611)	Cash paid for corporate income tax	(17,821)	(39,460)	(1,637)	(1,611)
Cash received for withholding tax         6,107         -         6,107         -	Cash received for withholding tax	6,107	<u> </u>	6,107	-
Net cash flows from (used in) operating activities         1,402         (108,767)         44,649         (13,724)	Net cash flows from (used in) operating activities	1,402	(108,767)	44,649	(13,724)

### Cash flow statements (continued)

For the nine-month period ended 30 September 2019

			(Unit: T	housand Baht)	
	Consolidated financial statements		Separate financial statements		
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Cash flows from investing activities:					
Increase in current investment	(43)	(43)	-	-	
Increase in short-term loans to related parties	-	-	(31,000)	(88,500)	
Cash received from sales of property, plant and equipment	3,453	3,101	87	1,078	
Cash paid for acquisition of property, plant and equipment	(124,775)	(492,868)	(22,410)	(396,448)	
Cash paid for acquisition of intangible assets	(1,494)	(5,022)	(18)	(13)	
Dividend received from subsidiaries	-	-	19,800	64,288	
Dividend received from associate	258,917	332,893	258,917	332,893	
Interest received	63	73	2,602	1,287	
Net cash flows from (used in) investing activities	136,121	(161,866)	227,978	(85,415)	
Cash flows from financing activities:					
Increase (decrease) in bank overdrafts and short-term loans					
from financial institutions	(84,846)	182,925	60,000	5,000	
Cash paid under finance lease agreements	(209)	-	(209)	-	
Cash receipts from long-term loans from financial institutions	406,747	372,686	56,747	372,686	
Repayment of long-term loans from financial instituions	(269,375)	(144,375)	(150,900)	(60,900)	
Dividend paid	(236,461)	(241,287)	(236,461)	(241,287)	
Net cash flows from (used in) financing activities	(184,144)	169,949	(270,823)	75,499	
Net increase (decrease) in cash and cash equivalents	(46,621)	(100,684)	1,804	(23,640)	
Cash and cash equivalents at beginning of period	105,836	199,464	21,595	64,661	
Cash and cash equivalents at end of period	59,215	98,780	23,399	41,021	
	-		-		
Supplemental cash flows information					
Non-cash transactions:					
Acquisition of equipment which cash has not been paid	3,486	14,387	526	9,075	
Acquisition of intangible assets which cash has not been paid	52	651	-	-	
Acquisition of asset under finance lease agreement	4,402	-	4,402	-	

# Tipco Foods Public Company Limited and its subsidiaries Notes to interim consolidated financial statements For the three-month and nine-month periods ended 30 September 2019

# 1. General information

# 1.1 Basis of preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

# 1.2 Basis of consolidation

The consolidated interim financial statements include the financial statements of Tipco Foods Public Company Limited and its subsidiaries and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2018.

# 1.3 New financial reporting standards

# (a) Financial reporting standards that became effective in the current period

During the period, the Company and its subsidiaries adopted the revised (revised 2018) and new financial reporting standards and interpretations which were effective for fiscal periods beginning on or after 1 January 2019. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. The adoption of these financial reporting standards did not have any significant impact on the financial statements of the Company and its subsidiaries. However, the new standard involves changes to key principles, which were summarised below.

## **TFRS 15 Revenue from Contracts with Customers**

TFRS 15 supersedes the following accounting standards together with related interpretations:

TAS 11 (revised 2017)	Construction Contracts
TAS 18 (revised 2017)	Revenue
TSIC 31 (revised 2017)	Revenue - Barter Transactions Involving Advertising Services
TFRIC 13 (revised 2017)	Customer Loyalty Programmes
TFRIC 15 (revised 2017)	Agreements for the Construction of Real Estate
TFRIC 18 (revised 2017)	Transfers of Assets from Customers

Entities are to apply this standard to all contracts with customers unless those contracts fall within the scope of other standards. The standard establishes a five-step model to account for revenue arising from contracts with customers, with revenue being recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The standard requires entities to exercise judgement, taking into consideration all of the relevant facts and circumstances when applying each step of the model.

This standard did not have any effect on profit or loss of the Company and its subsidiaries and resulted only in the reclassifications of the statement of comprehensive income for the three-month and nine-month periods ended 30 September 2019 as described below.

(Unit: Million Baht)

	For the three-month period ended 30 September 2019					
	Consolidated financial statements					
	Previous financial Increase					
	reporting standard	(decrease)	TFRS 15			
Statement of comprehensive income	e					
Profit or loss:						
Sales	881	(23)	858			
Cost of sales	742	3	745			
Selling and distribution expenses	146	(26)	120			

(Unit: Million Baht)

	For the nine-month period ended 30 September 2019					
	Consolidated financial statements					
	Previous financial Increase					
	reporting standard	(decrease)	TFRS 15			
Statement of comprehensive income						
Profit or loss:						
Sales	2,851	(74)	2,777			
Cost of sales	2,471	10	2,481			
Selling and distribution expenses	448	(84)	364			

# (b) Financial reporting standards that will become effective for fiscal years beginning on or after 1 January 2020

The Federation of Accounting Professions issued a number of new and revised financial reporting standards and interpretations, which are effective for fiscal years beginning on or after 1 January 2020. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards except the following new standards which involve changes to key principles, which are summarised below.

# Financial reporting standards related to financial instruments

A set of TFRSs related to financial instruments consists of five accounting standards and interpretations, as follows:

Financial reporting standards:

TFRS 9 Financial Instruments

Accounting standard:

TAS 32 Financial Instruments: Presentation

Financial Reporting Standard Interpretations:

TFRIC 16	Hedges of a Net Investm	nent in a Foreign Operation
----------	-------------------------	-----------------------------

TFRIC 19 Extinguishing Financial Liabilities with Equity Instruments

These TFRSs related to financial instruments make stipulations relating to the classification of financial instruments and their measurement at fair value or amortised cost (taking into account the type of instrument, the characteristics of the contractual cash flows and the entities's business model), calculation of impairment using the expected credit loss method, and hedge accounting. These include stipulations regarding the presentation and disclosure of financial instruments. When the TFRSs related to financial instruments are effective, some accounting standards, interpretations and guidance which are currently effective will be cancelled.

The management of the Company and its subsidiaries is currently evaluating the impact of these standards to the financial statements in the year when they are adopted.

# **TFRS 16 Leases**

TFRS 16 supersedes TAS 17 Leases together with related Interpretations. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases, and requires a lessee to recognise assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is low value.

Accounting by lessors under TFRS 16 is substantially unchanged from TAS 17. Lessors will continue to classify leases as either operating or finance leases using similar principles to those used under TAS 17.

The management of the Company and its subsidiaries is currently evaluating the impact of this standard on the financial statements in the year when it is adopted.

# 1.4 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2018.

# 2. Related party transactions

During the periods, the Company and its subsidiaries had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon among the Company, its subsidiaries and those related parties.

(Unit: Million Baht)

-	For the three-month periods ended 30 September				-
	Consolidated		Separate		
-	financial s	tatements	financial statements		Transfer pricing policy
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Transactions with subsidiaries					
(eliminated from the consolidated					
financial statements)					
Sales of goods	-	-	76	101	Cost plus certain margin
Management income	-	-	20	19	As agreed
Interest income	-	-	1	1	At rates of 2.3 - 3.7% per annum
Dividend income	-	-	-	37	Announced rate
Transactions with associate					
Rental and service expenses	1	1	-	-	Market price
Dividend income	-	-	148	-	Announced rate
Transactions with related companies					
Sales of goods	-	1	1	-	Market price
Rental and service expenses	10	12	5	4	Market price

## (Unit: Million Baht)

	For the n	ine-month perio	_		
	Conso	Consolidated Separate			
	financial s	tatements	financial s	tatements	Transfer pricing policy
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Transactions with subsidiaries					
(eliminated from the consolidated					
financial statements)					
Sales of goods	-	-	277	278	Cost plus certain margin
Management income	-	-	53	57	As agreed
Interest income	-	-	3	1	At rates of 2.3 - 3.7% per annum
Dividend income	-	-	20	64	Announced rate

# (Unaudited but reviewed)

## (Unit: Million Baht)

-	For the n	ine-month perio	-		
	Consolidated		Separate		
	financial statements		financial statements		Transfer pricing policy
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Transactions with associate					
Sales of goods	1	1	-	-	Market price
Rental and service expenses	1	1	-	-	Market price
Dividend income	-	-	259	333	Announced rate
Transactions with related companies					
Sales of goods	1	1	1	-	Market price
Rental and service expenses	32	33	13	11	Market price

The balances of the accounts as at 30 September 2019 and 31 December 2018 between the Company, its subsidiaries and those related parties were as follows:

	Consolidated		Sepa	arate
	financial s	tatements	financial s	tatements
	30 September	31 December	30 September	31 December
	2019	2018	2019	2018
		(Audited)		(Audited)
Trade and other receivables - related parties (Note 3)				
Subsidiaries	-	-	28,934	45,364
Associate	255	1,450	-	83
Related companies (common shareholders and directors)	146	1,089	-	-
Total trade and other receivables - related parties	401	2,539	28,934	45,447
Prepaid expenses - related parties				
Associate	-	224	-	224
Related companies (common shareholders and directors)	1,566	390	182	156
Total prepaid expenses - related parties	1,566	614	182	380
Retentions - related parties				
Related companies (common shareholders and directors)	9,610	8,460	3,409	2,828
Total retentions - related parties	9,610	8,460	3,409	2,828

# (Unaudited but reviewed)

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial s	financial statements		tatements
	30 September 31 December		30 September	31 December
	2019	2018	2019	2018
		(Audited)		(Audited)
Trade and other payables - related parties (Note 8)				
Subsidiaries	-	-	61	125
Associate	357	596	117	128
Related companies (common shareholders and directors)	2,495	1,763	233	432
Total trade and other payables - related parties	2,852	2,359	411	685

# Short-term loans to related parties

As at 30 September 2019 and 31 December 2018, the balances of short-term loans to related parties and the movements were as follows:

		Separate financial statements					
		Balance as at	Increase	Decrease	Balance as at		
Short-term loans to		31 December	during	during	30 September		
related parties	Related by	2018	the period	the period	2019		
		(Audited)					
Tipco Pineapple Co., Ltd.	Subsidiary	90,000	246,000	(252,000)	84,000		
Tipco Biotech Co., Ltd.	Subsidiary	-	31,000	(5,000)	26,000		
Tipco Retail Co., Ltd.	Subsidiary		11,000	-	11,000		
Total		90,000	288,000	(257,000)	121,000		

# Directors and management's benefits

For the three-month and nine-month periods ended 30 September 2019 and 2018, the Company and its subsidiaries had employee benefit expenses of their directors and management as detailed below.

	(Unit: Million Baht)				
	For the three-month periods ended 30 September				
	Consolidated Separate				
	financial statements		statements financial statem		
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Short-term employee benefits	8	9	6	6	
Post-employment benefits	1	-	-	-	
Total	9	9	6	6	

## (Unit: Million Baht)

	For the nine-month periods ended 30 September				
	Consol	idated	Sepa	rate	
	financial statements		financial statements		
	<u>2019</u> <u>2018</u>		<u>2019</u>	<u>2018</u>	
Short-term employee benefits	30	32	22	21	
Post-employment benefits	2	1	1	1	
Total	32	33	23	22	

# 3. Trade and other receivables

	Consolidated fina	ancial statements	Separate financial statements		
	30 September	30 September 31 December		31 December	
	2019	2018	2019	2018	
		(Audited)		(Audited)	
Trade receivables - related parties (Note 2)					
Aged on the basis of due dates					
Not yet due	243	2,290	22,000	37,826	
Past due					
Up to 3 months	92	166	-	-	
3 - 6 months	66	-	-	-	
Total trade receivables - related parties	401	2,456	22,000	37,826	

# (Unaudited but reviewed)

# (Unit: Thousand Baht)

	Consolidated fina	ancial statements	Separate finan	Separate financial statements	
	30 September	31 December	30 September	31 December	
	2019	2018	2019	2018	
		(Audited)		(Audited)	
Trade receivables - unrelated parties					
Aged on the basis of due dates					
Not yet due	300,385	390,157	-	3	
Past due					
Up to 3 months	37,901	80,094	-	-	
3 - 6 months	506	817	-	-	
6 - 12 months	-	501	-	-	
Over 12 months	617	779			
Total	339,409	472,348	-	3	
Less: Allowance for doubtful accounts	(386)	(887)		-	
Total trade receivables - unrelated parties, net	339,023	471,461		3	
Total trade receivables - net	339,424	473,917	22,000	37,829	
Other receivables					
Amounts due from related parties (Note 2)	-	83	6,934	7,621	
Amounts due from unrelated parties	59,214	87,194	14	4	
Advance to employees	840	674	99	19	
Accrued income	396	464	28	1	
Total other receivables	60,450	88,415	7,075	7,645	
Total trade and other receivables - net	399,874	562,332	29,075	45,474	

# 4. Inventories

Movements in the reduction of cost to net realisable value of inventories account during the nine-month period ended 30 September 2019 were summarised below.

		(Unit: Thousand Baht)
	Consolidated Separate	
	financial statements	financial statements
Balance as at 1 January 2019	39,326	3,066
Reduction of cost to net realisable value of inventory		
account during the period	20,922	887
Balance as at 30 September 2019	60,248	3,953

#### 5. Investments in subsidiaries

Details of investments in subsidiaries as presented in the separate financial statements are as follows:

					(Unit: T	housand Baht)
			Dividends	received	Dividends received	
			during the th	ree-month	during the n	ine-month
Company's name	Cc	ost	periods ended 3	30 September	periods ended 3	0 September
	30 September	31 December				
	2019	2018	2019	2018	2019	2018
		(Audited)				
Tipco F&B Co., Ltd.	729,050	729,050	-	28,800	19,800	49,200
Tipco Retail Co., Ltd.	175,500	175,500	-	-	-	-
Tipco Biotech Co., Ltd.	160,787	160,787	-	8,096	-	15,088
Tipco Pineapple Co., Ltd.	700,000	700,000	-			-
Total	1,765,337	1,765,337	-	36,896	19,800	64,288

#### 6. Investment in associate

#### 6.1 Details of associate:

Cost

#### (Unit: Thousand Baht) Consolidated financial statements Separate financial statements 30 September 31 December 30 September 31 December 2019 2018 2019 2018 (Audited) (Audited) 644,930 644,930 644,930 644,930 Carrying amounts based on 2,910,063 equity method 3,046,225

# 6.2 Share of profit and dividend received

During the three-month and nine-month periods ended 30 September 2019 and 2018, the Company has recognised its share of profit from investment in associate in the consolidated financial statements and dividend income in the separate financial statements as follows:

## (Unit: Thousand Baht)

	For the three-month periods ended 30 September			
	Consolidated finan	cial statements	Separate financi	al statements
	Share of profit fron	n investment in	Dividend re	eceived
Company's name	associate during the period		during the period b	y the Company
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Tipco Asphalt Plc.	166,872	1,165	147,953	-

(Unit: Thousand Baht)

	For the nine-month periods ended 30 September					
	Consolidated finar	ncial statements	Separate financi	ial statements		
	Share of profit from	m investment in	Dividend received			
Company's name	associate during the period		during the period b	by the Company		
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>		
Tipco Asphalt Plc.	582,530	101,684	258,917	332,893		

# 7. Property, plant and equipment

Movements of the property, plant and equipment account during the nine-month period ended 30 September 2019 were summarised below.

	(	(Unit: Thousand Baht)		
	Consolidated	Separate		
	financial statements	financial statements		
Net book value as at 1 January 2019	2,287,283	742,168		
Acquisitions during period - at cost	112,629	17,355		
Disposals/written-off during period - net book value at				
disposal/written-off date	(19,990)	-		
Depreciation for the period	(171,256)	(45,320)		
Net book value as at 30 September 2019	2,208,666	714,203		

# 8. Trade and other payables

			(Unit: Thousand Baht)			
	Consol	idated	Sepa	Separate		
	financial s	tatements	financial s	tatements		
	30 September	31 December	30 September	31 December		
	2019 2018 (Audited)		2019	2018		
				(Audited)		
Trade payables - related parties (Note 2)	-	-	23	85		
Trade payables - unrelated parties	137,969	274,251	11,601	29,755		
Amounts due to related parties (Note 2)	2,852	2,359	388	600		
Accrued expenses	246,660	372,249	37,011	33,043		
Others	152,040	141,270	3,336	13,386		
Total trade and other payables	539,521	790,129	52,359	76,869		

# 9. Long-term loans from financial institutions

Movements in the long-term loans from financial institutions account during the nine-month period ended 30 September 2019 were summarised below.

	(Unit: Thousand E			
	Consolidated	Separate		
	financial statements	financial statements		
Balance as at 1 January 2019	1,152,703	930,698		
Additions	406,747	56,747		
Repayments	(269,375)	(150,900)		
Balance as at 30 September 2019	1,290,075	836,545		
Less: Current portion	(405,000)	(223,700)		
Long-term loans from financial institutions				
- net of current portion	885,075	612,845		

On 5 February 2019, a subsidiary entered into a credit facility agreement for a long-term loan with a bank amounting to Baht 350 million to repay its short-term loans from banks. Such loan carries interest at a rate with reference to THBFIX and repayable on a quarterly basis starting from March 2019 until March 2024.

The loan is secured by the mortgage of the subsidiary's land and structuring thereon.

The loan agreement of the subsidiary contains certain restrictive covenants pertaining to, among other things, the maintenance of debt-to-equity ratio and debt service coverage ratio at the rate prescribed in the agreement.

# Loan covenants

The loan agreements of the Company and its subsidiaries contained certain restrictive covenants as were disclosed in the 2018 annual financial statements except the additional covenants under the new loan agreement as described above.

## 10. Credit facilities

The credit facilities of the Company and its subsidiaries granted by financial institutions are secured by the following collaterals:

- a) The guarantees by the Company and a subsidiary.
- b) The mortgages of the assets of the Company and its subsidiaries of which the net book value as at 30 September 2019 and 31 December 2018 were summarised below.

(Unit: Million Baht)

	Consolidated financial statements		Separate financial statements		
	30 September 2019	31 December 2018	30 September 2019	31 December 2018	
		(Audited)		(Audited)	
Land	105	63	17	17	
Buildings and complement	377	402	278	289	
Machinery and equipment	75	93	-	-	

c) The prohibition from creating lien over assets of the Company and its subsidiaries.

## 11. Provision for long-term employee benefits

Movements of the provision for long-term employee benefits account during the nine-month period ended 30 September 2019 are summarised below.

	(	Unit: Thousand Baht)
	Consolidated	Separate
	financial statements	financial statements
Provision for long-term employee benefits as at 1 January 2019	98,360	25,109
Included in profit or loss:		
Current service cost	8,669	2,969
Interest cost	2,265	554
Past service cost	23,869	5,300
Benefits paid during the period	(3,893)	(340)
Provision for long-term employee benefits as at 30 September 2019	129,270	33,592

During the second quarter of the current year, The Labor Protection Act (No. 7) B.E. 2562 was announced in the Royal Gazette. This stipulates additional legal severance pay rates for employees who have worked for an uninterrupted period of twenty years or more, with such employees entitled to receive not less than 400 days' compensation at the latest wage rate. This change is considered a post-employment benefits plan amendment and the Company and its subsidiaries reflected the effect of the change by recognising past service costs of Baht 24 million (The Company only: Baht 5 million) as expenses in the statements of comprehensive income in the second quarter of the current year.

# 12. Income tax

Income tax expenses for the three-month and nine-month periods ended 30 September 2019 and 2018 were made up as follows:

	(Unit: Thousand Bah			
	For the three	-month perio	ds ended 30 S	September
	Consolio	dated	Separ	ate
	financial sta	atements	financial sta	atements
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Current income tax:				
Current income tax charge	(2,090)	4,939	-	-
Deferred tax:				
Relating to origination and reversal of				
temporary differences	(1,585)	(870)	(91)	(379)
Income tax expenses (benefit) reported in				
the statements of comprehensive income	(3,675)	4,069	(91)	(379)

	For the nine-month periods ended 30 September					
	Consoli	dated	Separate			
	financial sta	atements	financial sta	atements		
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>		
Current income tax:						
Current income tax charge	3,386	7,021	-	-		
Adjustment in respect of income tax of						
previous year	-	30,001	-	-		
Deferred tax:						
Relating to origination and reversal of						
temporary differences	(7,453)	2,694	(1,706)	1,125		
Income tax expenses (benefit) reported in						
the statements of comprehensive income	(4,067)	39,716	(1,706)	1,125		

# 13. Dividends

			Dividend
Dividends	Approved by	Total dividends	per share
		(Million Baht)	(Baht per share)
Final dividends for 2017	Annual General Meeting of the		
	shareholders on 10 April 2018	241.3	0.50
Total dividends for the nine-m	nonth period ended		
30 September 2018		241.3	0.50
Final dividends for 2018	Annual General Meeting of the		
	shareholders on 4 April 2019	120.6	0.25
Interim dividends for 2019	Board of Directors' meeting		
	on 14 August 2019	115.8	0.24
Total dividends for the nine-m	onth period ended		
30 September 2019		236.4	0.49

# 14. Segment information

The following tables present revenue and profit information regarding the Company and its subsidiaries' operating segments for the three-month and nine-month periods ended 30 September 2019 and 2018, respectively.

(Unit: Million Baht)

	For the three-month periods ended 30 September								
	Produ	cts of							
	vegetable	e & fruit	Beve	rage	Oth	ers	Consoli	dation	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Revenues from sales of goods	366	457	484	600	8	31	858	1,088	
Gross profit (loss)	(10)	98	121	159	1	9	112	266	
Other income							28	38	
Selling and distribution expenses							(120)	(149)	
Administrative expenses and other expenses							(114)	(106)	
Profit (loss) before share of profit from									
investment in associate, finance cost and									
income tax expenses							(94)	49	
Share of profit from investment in associate							167	1	
Profit before finance cost and income tax expenses							73	50	
Finance cost							(18)	(16)	
Income tax benefit (expenses)							4	(4)	
Profit for the period							59	30	

# (Unaudited but reviewed)

(Unit: Million Baht)

	For the nine-month periods ended 30 September							
	Produ	cts of						
	vegetabl	e & fruit	Beverage		Others		Consolidation	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Revenues from sales of goods	1,186	1,270	1,561	1,760	30	95	2,777	3,125
Gross profit (loss)	(87)	138	378	499	4	29	295	666
Other income							107	95
Selling and distribution expenses							(364)	(466)
Administrative expenses and other expenses							(342)	(307)
Loss before share of profit from								
investment in associate, finance cost and								
income tax expenses							(304)	(12)
Share of profit from investment in associate							583	102
Profit before finance cost and income tax expenses							279	90
Finance cost							(53)	(40)
Income tax benefit (expenses)							4	(40)
Profit for the period							230	10

Geographic segment information for the three-month and nine-month periods 30 September 2019 and 2018 was as follows:

	For the three-month periods ended 30 September							
	Domest	ic sales	Export	sales	Consolidation			
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>		
Revenues from the sale of goods	427	577	431	511	858	1,088		
Gross profit	103	161	9	105	112	266		

(Unit: Million Baht)

(Unit: Million Baht)

	For the nine-month periods ended 30 September						
	Domest	ic sales	Export sales		Consolidation		
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>	
Revenues from the sale of goods	1,415	1,697	1,362	1,428	2,777	3,125	
Gross profit (loss)	344	481	(49)	185	295	666	

Transfer prices between the segments are set out in Note 2 to the interim financial statements.

# 15. Commitments and contingent liabilities

## **15.1 Capital commitments**

The Company and its subsidiaries had outstanding capital commitments relating to building complement, purchases of machinery and equipment and computer software as follows:

				(Unit: Million)
	Consolidated fina	ancial statements	Separate finan	cial statements
Foreign currency	30 September 2019	31 December 2018	30 September 2019	31 December 2018
		(Audited)		(Audited)
Baht	10	14	-	12

# 15.2 Operating lease commitments

The Company and its subsidiaries have entered into several agreements in respect of the lease of land, buildings, warehouses, motor vehicles, office equipment, and other service agreements.

Future minimum rental and service fees payable under these agreements were as follows:

(Unit: Million Baht)

	Consolidated fina	ancial statements	Separate financial statements		
	30 September 2019	31 December 2018	30 September 2019	31 December 2018	
		(Audited)		(Audited)	
Payable within:					
1 year	69	76	29	26	
2 to 5 years	61	103	26	36	

# 15.3 Bank guarantees

The outstanding bank guarantees issued by the banks on behalf of the Company and its subsidiaries in respect of certain performance bonds as required in the normal course of business were summarised below.

				(Unit: Million Baht)
	Consolidated fina	ancial statements	Separate finan	cial statements
	30 September 2019	31 December 2018	30 September 2019	31 December 2018
		(Audited)		(Audited)
Bank guarantees	20	54	7	11

# 16. Foreign currency risk

The balances of financial assets and liabilities of the Company and its subsidiaries denominated in foreign currencies were summarised below.

		Consolidated fina					
	Financia	al assets	Financial	liabilities	Average exchange rate		
	30 September	31 December	30 September	31 December	30 September	31 December	
Foreign currency	2019	2018	2019	2018	2019	2018	
	(Million)	(Million)	(Million)	(Million)	(Baht per 1 forei	gn currency unit)	
		(Audited)		(Audited)		(Audited)	
US Dollar	4.0	5.1	0.4	1.1	30.59	32.45	
Euro	1.3	-	0.1	0.2	33.43	37.13	
Yen	-	-	0.2	-	0.28	-	
Australian Dollar	-	-	0.1	-	20.66	-	

The outstanding forward exchange contracts of the Company and its subsidiaries which maturity date within one year were summarised below.

	As at 30 September 2019						
	Conso	lidated	Sep	arate			
	financial s	statements	financial s	inancial statements Contractual exch		exchange rate	
	Sold	Bought	Sold	Bought			
Foreign currency	Amount	amount	amount	amount	Sold	Bought	
	(Million)	(Million)	(Million)	(Million)	(Baht per 1 forei	gn currency unit)	
US Dollar	3.4	-	-	-	30.38 - 31.89	-	
			As at 31 December 201		8 (Audited)		
	Conso	lidated	Sepa	arate			
	financial s	tatements	financial s	tatements	Contractual e	exchange rate	
	Sold	Bought	Sold	Bought			
Foreign currency	amount	amount	amount	amount	Sold	Bought	
	(Million)	(Million)	(Million)	(Million)	(Baht per 1 foreig	gn currency unit)	
US Dollar	1.7	0.4	-	-	32.27 - 33.01	32.31 - 32.98	
Euro	-	0.1	-	-	-	37.60	

As at 30 September 2019, the subsidiaries had put option and call option contracts and the outstanding is summarised below.

	Sold	Bought	Contractual exchange rate       Sold     Bought		Unrealised loss on
Contracts	amount	amount			change in fair value
	(Million U	S Dollar)	(Baht per 1 foreigr	n currency unit)	(Million Baht)
Put option	3.0	-	30.90 - 31.50	-	0.3
Call option	-	2.0	-	31.70	2.2

# 17. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 13 November 2019.